Management - Abzena
Jonathan Goldman, Abzena Board Member

Jonathan Goldman

Chief Executive Officer

Jonathan Goldman joins Abzena from his role as an Operating Partner at Welsh Carson where he focused on healthcare investments. He joined WCAS in 2017 following the sale of Aptuit, a former WCAS portfolio company. Jonathan served as the Chief Executive Officer of Aptuit, an integrated small molecule discovery, development and manufacturing CRO from 2013 to 2017, that also operated a sterile fill finish facility. He has 29 years of experience in healthcare. He previously held senior executive positions at ICON Plc, including Global Head of Sales and Point Biomedical, where he served as Chief Medical Officer. Until 2018 he also held appointments as an Associate Clinical Professor of Medicine in the division of Cardiology at the University of California, San Francisco and as an Attending Cardiologist at the San Francisco Veterans Administration Medical Center, following appointments at the John Radcliffe Hospital, Oxford UK as a Consultant Cardiologist.

Jonathan grew up in London where he trained in medicine at St. Bartholomew’s’ Hospital Medical College and in Cardiology at St. George’s Hospital, London. He received BSc, MBBS and MD degrees from the University of London. He also was awarded MBA degrees from Columbia University in New York and the University of California at Berkeley. He serves on the Cardiovascular Research Advisory Board, Oregon Health Sciences University and the Healthcare Pharmaceutical Management advisory board at Columbia University Business School.

Michelle Neaves, Abzena Board Member

Michelle Neaves

Head of Finance

Michelle joined Abzena in October 2016 after 19 years’ experience at PwC Cambridge where she qualified as a Chartered Accountant. Michelle was a senior manager specialising in the life science sector with extensive capital markets experience, including fund-raising, Class 1 acquisitions and disposals and bond issues for main-market and AiM listed groups, as well as working with private equity backed businesses and UK private companies. Michelle holds a BSc in Biology from the University of York.

Sven Lee, Abzena Board Member

Sven Lee

Chief Business Officer

Before joining Abzena, Sven was Director, Global Sales and Business Development for the Cell Therapy Technologies business unit of Terumo BCT. He was successful in growing business and new collaborations within cell therapy and immunotherapy.

Prior to Terumo BCT, Sven was Vice President, Global Business Development at Catalent Biologics, responsible for the team's pre-clinical through Phase I/II GMP manufacturing business. He also launched the SMART Tag® antibody drug conjugation platform. Before Catalent, Sven spent five years as Director, Business Development, with Crucell (Johnson & Johnson) and ten years with Biogen.

Sven started his career, after graduating with a BA in biology from Lake Forest College.

Campbell Bunce, Abzena Board Member

Campbell Bunce

Senior VP Scientific Operations

Campbell has over 19 years’ experience working in the biotech and diagnostics sectors, occupying senior management positions with Piramed Pharma (Director, Development Programmes), Immune Targeting Systems (R & D Director) and Oxford Immunotec (General Manager, Immunology Products). He has extensive experience in developing novel biologics and vaccines for cancer, inflammatory and infectious diseases, leading them through development and regulatory processes including pre-clinical evaluation and translation in the clinic.
Campbell has a PhD in Immunology from the University of Manchester and has published a number of papers in T cell biology, immunomodulators and vaccines.

Sanjeevani Ghone, Abzena Board Member

Sanjeevani Ghone

Vice President of Chemistry and Site Head

Sanjeevani joined The Chemistry Research Solution LLC (acquired by Abzena in 2015) in early 2010 as Principal Scientist and was successively promoted to Director of Chemistry and in 2016 to Vice President of Chemistry and Site Head. She has worked on a host of projects involving toxic payloads and antibody-drug conjugates along with other multi-step organic syntheses and has gained extensive experience in solving complex organic chemistry problems.

Sanjeevani has more than 20 years’ experience working in chemical, pharmaceutical, and biotech companies as well as academic institutes. She has held R&D executive positions at Imperial Chemical International and Bombay Drug House. During her academic career, Sanjeevani was a Professor in Pharmaceutical Chemistry at academic institutions where she mentored MS and PhD students as research advisor.

Sanjeevani has a PhD in Medicinal Chemistry from the Institute of Chemical Technology, University of Mumbai. She has published a number of research/review articles on multi-step organic synthesis of novel molecules, lead optimization, payload-linker chemistry and computer-aided drug design (CADD) for a variety of therapeutic areas and also co-authored a book on the synthon approach to the synthesis of drugs.

Kristy Myers Bell, Abzena Board Member

Kristy Myers Bell

Vice President Operations and Site Head, San Diego

Kristy brings 25 years of pharmaceutical experience in operations and supply chain management for the manufacture of biologics and small molecules.

Prior to joining Abzena, Kristy led the Manufacturing Operations team at Catalent, San Diego and launched the site’s Continuous Improvement program. She spent 10 years at Genentech in biologics manufacturing, supply chain operations and lean six sigma. Kristy was an Operational Excellence Leader for Advanced BioHealing / Shire.

She holds a B.S. degree in Molecular and Cell Biology from the University of California, Berkeley, and an MBA from California State University at Hayward.

Interested in our services? Get In Touch